Find Doravirine manufacturers, exporters & distributors on PharmaCompass

Doravirine

Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

4 API Suppliers, 2 USDMF, 4 NDC API, 2 Listed Suppliers

4 API Suppliers
2 USDMF
4 NDC API
2 Listed Suppliers

DEVELOPMENTS

8 Drugs in Development

8 Drugs in Development

INTERMEDIATES

4 Intermediates Suppliers

4 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

4 FDF Dossiers, 2 FDA Orange Book, 2 Canada

4 FDF Dossiers
2 FDA Orange Book
2 Canada

DIGITAL CONTENT

20 NEWS #PharmaBuzz

media
20 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions

globalSalesInformation
1 US Medicaid Prescriptions

MARKET PLACE

1 APIs

marketPlace
1 APIs

PATENTS & EXCLUSIVITIES

8 US Patents, 2 US Exclusivities

patents
8 US Patents
2 US Exclusivities

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

59,531,704

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 1338225-97-0, Mk-1439, Pifeltro, 3-chloro-5-((1-((4-methyl-5-oxo-4,5-dihydro-1h-1,2,4-triazol-3-yl)methyl)-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl)oxy)benzonitrile, 3-chloro-5-[1-[(4-methyl-5-oxo-1h-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)pyridin-3-yl]oxybenzonitrile, Mk1439

Molecular Formula

C₁₇H₁₁ClF₃N₅O₃

Molecular Weight

425.7 g/mol

InChI Key

ZIAOVIPSKUPPQW-UHFFFAOYSA-N

FDA UNII

913P6LK81M

Doravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) intended to be administered in combination with other antiretroviral medicines. Doravirine is available by itself or as a combination product of doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg). Doravirine is formally indicated for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment experience, further expanding the possibility and choice of therapeutic treatments available for the management of HIV-1 infection.

Doravirine is a Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor. The mechanism of action of doravirine is as a Non-Nucleoside Reverse Transcriptase Inhibitor.

1 2D Structure

Doravirine

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

3-chloro-5-[1-[(4-methyl-5-oxo-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)pyridin-3-yl]oxybenzonitrile

2.1.2 InChI

InChI=1S/C17H11ClF3N5O3/c1-25-13(23-24-16(25)28)8-26-3-2-12(17(19,20)21)14(15(26)27)29-11-5-9(7-22)4-10(18)6-11/h2-6H,8H2,1H3,(H,24,28)

2.1.3 InChI Key

ZIAOVIPSKUPPQW-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CN1C(=NNC1=O)CN2C=CC(=C(C2=O)OC3=CC(=CC(=C3)C#N)Cl)C(F)(F)F

2.2 Other Identifiers

2.2.1 UNII

913P6LK81M

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Mk-1439

2. Pifeltro

2.3.2 Depositor-Supplied Synonyms

1. 1338225-97-0

2. Mk-1439

3. Pifeltro

4. 3-chloro-5-((1-((4-methyl-5-oxo-4,5-dihydro-1h-1,2,4-triazol-3-yl)methyl)-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl)oxy)benzonitrile

5. 3-chloro-5-[1-[(4-methyl-5-oxo-1h-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)pyridin-3-yl]oxybenzonitrile

6. Mk1439

7. Doravirine (mk-1439)

8. Mk-1439a

9. 913p6lk81m

10. 3-chloro-5-({1-[(4-methyl-5-oxo-4,5-dihydro-1h-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl}oxy)benzonitrile

11. Benzonitrile, 3-chloro-5-((1-((4,5-dihydro-4-methyl-5-oxo-1h-1,2,4-triazol-3-yl)methyl)-1,2-dihydro-2-oxo-4-(trifluoromethyl)-3-pyridinyl)oxy)-

12. Doravirine [usan]

13. Doravirine [usan:inn]

14. Unii-913p6lk81m

15. 4ncg

16. Pifeltro (tn)

17. 2kw

18. Mk 1439

19. Doravirine [mi]

20. Doravirine [inn]

21. Doravirine [jan]

22. Doravirine; Mk-1439

23. Mk-1439(doravirine)

24. Doravirine [who-dd]

25. C17h11clf3n5o3

26. Doravirine (jan/usan/inn)

27. Schembl2509885

28. Chembl2364608

29. Doravirine [orange Book]

30. Dtxsid30158386

31. Amy16781

32. Bcp02296

33. Ex-a1968

34. Bdbm50508293

35. Delstrigo Component Doravirine

36. Mfcd22417167

37. S6492

38. Zinc72317283

39. Akos030528603

40. Cs-5924

41. Db12301

42. Sb17104

43. Doravirine Component Of Delstrigo

44. Ncgc00508866-01

45. Ac-33637

46. Hy-16767

47. Db-091410

48. D10624

49. F53303

50. A856128

51. Q6885419

52. S900006160

53. 3-chloro-5-[[1-[(4-methyl-5-oxo-1h-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-3-pyridyl]oxy]benzonitrile

2.4 Create Date

2012-08-19

3 Chemical and Physical Properties

Molecular Formula	C₁₇H₁₁ClF₃N₅O₃
Molecular Weight	425.7 g/mol
XLogP3	2.1
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	4
Exact Mass	425.0502514 g/mol
Monoisotopic Mass	425.0502514 g/mol
Topological Polar Surface Area	98 Å²
Heavy Atom Count	29
Formal Charge	0
Complexity	860
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Doravirine is indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment history. It is also indicated to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to doravirine.

FDA Label

Pifeltro is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older weighing at least 35 kg infected with HIV 1 without past or present evidence of resistance to the NNRTI class.

5 Pharmacology and Biochemistry

5.1 Pharmacology

In a clinical phase 2 trial evaluating a dose range of 0.25-2x the recommended dose of doravirine (in combination with emtricitabine/tenofovir) in HIV-1 infected subjects with no antiretroviral treatment history, no exposure-response relationship for efficacy was identified for doravirine. Furthermore, at a dose of 1200 mg, which provides approximately 4 times the peak concentration observed following the recommended dose, doravirine does not prolong the QT interval to any clinically relevant extent.

5.2 FDA Pharmacological Classification

5.2.1 Active Moiety

DORAVIRINE

5.2.2 FDA UNII

913P6LK81M

5.2.3 Pharmacological Classes

Non-Nucleoside Analog [EXT]; Non-Nucleoside Reverse Transcriptase Inhibitors [MoA]; Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

5.3 ATC Code

J05AG06

J - Antiinfectives for systemic use

J05 - Antivirals for systemic use

J05A - Direct acting antivirals

J05AG - Non-nucleoside reverse transcriptase inhibitors

J05AG06 - Doravirine

5.4 Absorption, Distribution and Excretion

Absorption

The absolute bioavailability of doravirine is 64% with a T_max of 2 hours. Following oral [14C]doravirine administration, all of the administered dose was recovered and the agent is considered to be well absorbed. Moreover, its co-administration with food did not greatly alter doravirine's pharmacokinetic profile during clinical studies.

Route of Elimination

The primary route of elimination for doravirine is via cytochrome P450 3A4/5 metabolism. Only 6% of an administered dose is recovered in the urine unchanged, with even less unchanged drug found in the feces.

Volume of Distribution

The steady-state volume of distribution of doravirine following intravenous administration is 60.5 L.

Clearance

The oral and renal clearances of doravirine are 106 ml/min and 9.3 ml/min, respectively.

5.5 Metabolism/Metabolites

Following absorption, unchanged parent drug is the major circulating component in plasma. Its M9 metabolite - a product of cytochrome P450 3A4/5 mediated oxidative metabolism - is the most abundant doravirine metabolite in the circulation.

5.6 Biological Half-Life

The elimination half-life determined of doravirine is 15 hours.

5.7 Mechanism of Action

Doravirine is a pyridinone non-nucleoside reverse transcriptase inhibitor of HIV-1. Reverse transcriptase is the enzyme with which HIV generates complementary DNA (cDNA) to its RNA genome - this cDNA is then inserted into the host cell genome, where it can be transcribed into viral RNA for the purposes of replication. Doravirine inhibits HIV-1 replication by non-competitively inhibiting HIV-1 reverse transcriptase. Doravirine does not, however, inhibit the human cellular DNA polymerases , , and mitochondrial DNA polymerase .

API SUPPLIERS